nach oben

Current Allergy and Asthma Reports

Erschienen in:

11.09.2024 | Review

Epidemiology, Risk Factors, and Management of Biphasic Anaphylaxis

verfasst von: Matthew P. Giannetti

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Biphasic anaphylaxis is a variant of anaphylaxis characterized by recurrence of symptoms after initial resolution of anaphylaxis. It was first described in the mid 1990s by Popa and Lerner. Our understanding of the pathophysiology and epidemiology of the condition has advanced considerably since then. The purpose of this manuscript is to review the literature surrounding biphasic anaphylaxis while highlighting key works and recent advances.

Recent Findings

Prior studies have estimated biphasic anaphylaxis occurs in 0.4–20% of anaphylaxis episodes. The wide range may be related to differences in anaphylaxis diagnostic criteria which was inconsistent across studies. Recently identified risk factors for occurrence of biphasic anaphylaxis include severe initial symptoms including hypotension or hypoxia, delay in epinephrine use, and greater than one dose of epinephrine required to treat symptoms.

Summary

Despite our progress to better understand biphasic anaphylaxis, there remain gaps in the literature. This article aims to review the recent literature including, epidemiology, risk factors, and management of biphasic anaphylaxis.

Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082–123. https://doi.org/10.1016/j.jaci.2020.01.017.CrossRefPubMed

Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Annals of Allergy, Asthma & Immunology 2023. https://doi.org/10.1016/j.anai.2023.09.015.

Dribin TE, Sampson HA, Camargo CA, et al. Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2020;146(5):1089–96. https://doi.org/10.1016/j.jaci.2020.08.015.CrossRefPubMedPubMedCentral

Popa V, Lerner S. Biphasic systemic anaphylactic reactions: three illustrative cases. Ann Allergy. 1984;53:151–5.PubMed

Stark B, Sullivan T. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol. 1986;78:76–83.CrossRefPubMed

Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95:217–26.CrossRefPubMed

Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. Ann Emerg Med. 2006;47(4):373–80. https://doi.org/10.1016/j.annemergmed.2006.01.018.CrossRefPubMed

Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal 2020;13(10). https://doi.org/10.1016/j.waojou.2020.100472.

Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–6. https://doi.org/10.1016/j.jaci.2004.04.029.CrossRefPubMed

10.

Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;26:466–9.CrossRef

11.

Gold MS, Amarasinghe A, Greenhawt M, et al. Anaphylaxis: Revision of the Brighton collaboration case definition. Vaccine. 2023;41(15):2605–14. https://doi.org/10.1016/j.vaccine.2022.11.027.CrossRefPubMed

12.

Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124–76. https://doi.org/10.1016/j.anai.2023.09.015.CrossRefPubMed

13.

Lee S, Sadosty AT, Campbell RL. Update on biphasic anaphylaxis. Curr Opin Allergy Clin Immunol. 2016;16(4):346–51. https://doi.org/10.1097/aci.0000000000000279.CrossRefPubMed

14.

Alqurashi W, Stiell I, Chan K, Neto G, Alsadoon A, Wells G. Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. Ann Allergy Asthma Immunol. 2015;115(3):217-223.e2. https://doi.org/10.1016/j.anai.2015.05.013.CrossRefPubMed

15.

Lee S, Peterson A, Lohse CM, Hess EP, Campbell RL. Further Evaluation of Factors That May Predict Biphasic Reactions in Emergency Department Anaphylaxis Patients. J Allergy Clin Immunol In Practice. 2017;5(5):1295–301. https://doi.org/10.1016/j.jaip.2017.07.020.CrossRef

16.

Grunau BE, Li J, Yi TW, et al. Incidence of Clinically Important Biphasic Reactions in Emergency Department Patients With Allergic Reactions or Anaphylaxis. Ann Emerg Med. 2014;63(6):736-744.e2. https://doi.org/10.1016/j.annemergmed.2013.10.017.CrossRefPubMed

17.

Rossi CM, Lenti MV, Di Sabatino A. Adult anaphylaxis: A state-of-the-art review. Eur J Intern Med. 2022;100:5–12. https://doi.org/10.1016/j.ejim.2022.03.003.CrossRefPubMed

18.

Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis—a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341–84. https://doi.org/10.1016/j.anai.2015.07.019.CrossRefPubMed

19.

Moon TC, Dean Befus A, Kulka M. Mast cell mediators: Their differential release and the secretory pathways involved. Frontiers in Immunology 2014;5(NOV):1–18. https://doi.org/10.3389/fimmu.2014.00569.

20.

Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015;373(2):163–72. https://doi.org/10.1056/NEJMra1409760.CrossRefPubMed

21.

Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–54. https://doi.org/10.1038/nature07204.CrossRefPubMedPubMedCentral

22.

Brown SGA, Stone SF, Fatovich DM, et al. Anaphylaxis: Clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013;132(5):1141-1149.e5. https://doi.org/10.1016/j.jaci.2013.06.015.CrossRefPubMed

23.

Lee J, Greenes D. Biphasic anaphylactic reactions in pediatrics. Pediatrics. 2000;106(4):762–6.CrossRefPubMed

24.

Vezir E, Erkoçoğlu M, Kaya A, et al. Characteristics of anaphylaxis in children referred to a tertiary care center. Allergy Asthma Proc. 2013;34(3):239–46.CrossRefPubMed

25.

Plumb B, Bright P, Gompels MM, Unsworth DJ. Correct recognition and management of anaphylaxis: not much change over a decade. Postgrad Med J. 2015;91(1071):3–7. https://doi.org/10.1136/postgradmedj-2013-132181.CrossRefPubMed

26.

Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46(8):1099–110. https://doi.org/10.1111/cea.12748.CrossRefPubMed

27.

Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30(8):1144–50. https://doi.org/10.1046/j.1365-2222.2000.00864.x.CrossRefPubMed

28.

Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075–83. https://doi.org/10.1016/j.jaci.2013.10.029.CrossRefPubMed

29.

Alqurashi W, Ellis AK. Do Corticosteroids Prevent Biphasic Anaphylaxis? The Journal of Allergy and Clinical Immunology. In Pract. 2017;5(5):1194–205. https://doi.org/10.1016/j.jaip.2017.05.022.CrossRef

30.

Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol. 2007;98:64–9.CrossRefPubMed

31.

Gauvreau GM, Boulet L, Fitzgerald JM, et al. A dual CysLT 1 / 2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma. Allergy. 2016;71(12):1721–7. https://doi.org/10.1111/all.12987.CrossRefPubMed

32.

Gauvreau GM, El-Gammal AI, O’Byrne PM. Allergen-induced airway responses. Eur Respir J. 2015;46(3):819–31. https://doi.org/10.1183/13993003.00536-2015.CrossRefPubMed

33.

Bartholomew S, Young A. Evaluation of Prehospital Management in a Canadian Emergency Department Anaphylaxis Cohort. J Emerg Med. 2020;58(1):172–3. https://doi.org/10.1016/j.jemermed.2019.12.012.CrossRefPubMed

34.

Grabenhenrich L, Hompes S, Gough H, et al. Implementation of anaphylaxis management guidelines: a register-based study. PLoS ONE. 2012;7(5):e35778. https://doi.org/10.1371/journal.pone.0035778.CrossRefPubMedPubMedCentral

35.

Aregbesola A, Tam CM, Kothari A, Le ML, Ragheb M, Klassen TP. Glucocorticoids for croup in children. Cochrane Database Syst Rev. 2023;1(1):CD001955. https://doi.org/10.1002/14651858.CD001955.pub5.CrossRefPubMed

36.

Gates A, Gates M, Vandermeer B, et al. Glucocorticoids for croup in children. Cochrane Database Syst Rev. 2018;8(8):CD001955. https://doi.org/10.1002/14651858.CD001955.pub4.CrossRefPubMed

37.

Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2010;65(10):1205–11. https://doi.org/10.1111/j.1398-9995.2010.02424.x.CrossRefPubMed

38.

Sidhu N, Jones S, Perry T, et al. Evaluation of Anaphylaxis Management in a Pediatric Emergency Department. Pediatric Emergency Care. 2016;32(8):508–13.CrossRefPubMed

39.

Campbell RL, Hagan JB, Manivannan V, et al. Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol. 2012;129(3):748–52. https://doi.org/10.1016/j.jaci.2011.09.030.CrossRefPubMed

40.

Campbell RL, Luke A, Weaver AL, et al. Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis. Ann Allergy Asthma Immunol. 2008;101:631–6.CrossRefPubMedPubMedCentral

41.

Garvey L, Belhage B, Kroigaard M, Husum B, Malling H-J, Mosbech H. Treatment with Epinephrine (adrenaline) in suspected anaphylaxis during anesthesia in Denmark. Anesthesiology. 2011;115(1):111–6.CrossRefPubMed

42.

Banerji A, Rudders S, Clark S, Wei W, Long AA, Camargo CA. Retrospective Study of Drug-induced Anaphylaxis Treated in the Emergency Department or Hospital: Patient Characteristics, Management, and 1-Year Follow-up. J Allergy Clin Immunol: In Practice. 2014;2(1):46–51. https://doi.org/10.1016/j.jaip.2013.08.012.CrossRef

43.

Lieberman PL. Recognition and first-line treatment of anaphylaxis. Am J Med. 2014;127(1 SUPPL.):S6–11. https://doi.org/10.1016/j.amjmed.2013.09.008.CrossRefPubMed

44.

Douglas DM, Sukenick E, Andrade P, Brown J. Biphasic systemic anaphylaxis: An inpatient and outpatient study. J Allergy and Clin Immunol. 1994;93:977–85.CrossRef

45.

Rohacek M, Edenhofer H, Bircher A, Bingisser R. Biphasic anaphylactic reactions: occurrence and mortality. Allergy. 2014;69(6):791–7. https://doi.org/10.1111/all.12404.CrossRefPubMed

46.

Confino-Cohen R, Goldberg A. Allergen immunotherapy–induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol. 2010;104(1):73–8. https://doi.org/10.1016/j.anai.2009.11.001.CrossRefPubMed

47.

Kim T-H, Yoon Soon H, Hong H, Kang H-R, Cho S-H, Lee S-Y. Duration of Observation for Detecting a Biphasic Reaction in Anaphylaxis: A Meta-Analysis. Int Arch Allergy Immunol. 2019;179(1):31–6. https://doi.org/10.1159/000496092.CrossRefPubMed

Titel: Epidemiology, Risk Factors, and Management of Biphasic Anaphylaxis
verfasst von: Matthew P. Giannetti
Publikationsdatum: 11.09.2024
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 12/2024
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-024-01179-1

Neu im Fachgebiet HNO

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

08.01.2025
HNO-Tumoren
Nachrichten

Eine aktuelle Studie des Universitätsklinikums Erlangen verdeutlicht, dass Langzeitüberlebende von Kopf-Hals-Tumoren eine geringe Symptomlast aufweisen. Die am häufigsten auftretenden Beschwerden – Müdigkeit, Angstzustände, Schläfrigkeit und Schmerzen – sollten von den behandelnden Ärztinnen und Ärzten gezielt adressiert werden.

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

07.01.2025
Obstruktive Schlafapnoe
Nachrichten

Tritt eine obstruktive Schlafapnoe vor allem in einer bestimmten Seitenlage auf, kann dies auch an einem verbogenen Nasenseptum liegen. Eine Septumplastik lindert die Beschwerden mitunter deutlich.

Das alles ändert sich für Arztpraxen in 2025

31.12.2024
EBM
Nachrichten

Ab Januar greifen jede Menge Neuerungen – ob im EBM, Arbeits- und Steuerrecht oder bei der digitalen Vernetzung. Darunter einige Verbesserungen, aber teils auch Mehraufwand. „Same procedure as every year?“ – Ein Überblick.

Wie gefährlich sind suspekte Veränderungen in der Mundhöhle?

17.12.2024
Mundhöhlenkarzinom
Nachrichten

Wie hoch ist das Risiko, dass sich aus einer bereits verdächtigen Veränderung der Mundschleimhaut ein Karzinom entwickelt? Ein US-Team hat dazu das Patientenregister der Universität San Francisco ausgewertet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Epidemiology, Risk Factors, and Management of Biphasic Anaphylaxis

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 12/2024

Neu im Fachgebiet HNO

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

Das alles ändert sich für Arztpraxen in 2025

Wie gefährlich sind suspekte Veränderungen in der Mundhöhle?

Update HNO

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

Das alles ändert sich für Arztpraxen in 2025

Wie gefährlich sind suspekte Veränderungen in der Mundhöhle?

Update HNO